Search Results - "Thakkar, Snehal"

Associations with other cancer-related biomarkers might contribute to poor outcomes in RAS-altered, younger patients with colorectal cancer by Kundranda, Madappa N, Kemkes, Ariane C, Evans, Mark C, Flannery, Cynthia A, Hall, David W, Hoag, Jess R, Therala, Nishitha, Thakkar, Snehal G, De La O, Jean-Paul

“…Colorectal cancer (CRC) is a common cancer in younger adults. In patients undergoing liver resection with RAS-altered CRCs, there is evidence suggesting…”
Get full text

Value of next generation sequencing (NGS) testing in advanced cancer patients by Ortendahl, Jesse D, Cuyun Carter, Gebra, Thakkar, Snehal G, Bognar, Katalin, Hall, David W, Abdou, Yara

“…The availability of targeted therapies for oncology patients is increasing. Available genomic tests to identify treatment-eligible patients include single gene…”
Get more information

Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome by Davidson, Michael B, Thakkar, Snehal, Hix, John K, Bhandarkar, Naveen D, Wong, Alan, Schreiber, Martin J

“…Tumor lysis syndrome is an oncologic emergency that is characterized by severe electrolyte abnormalities and, frequently, by acute renal failure. The syndrome…”
Get more information

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma by Choueiri, Toni K., Dreicer, Robert, Rini, Brian I., Elson, Paul, Garcia, Jorge A., Thakkar, Snehal G., Baz, Rachid C., Mekhail, Tarek M., Jinks, Holly A., Bukowski, Ronald M.

“…BACKGROUND. Lenalidomide (LEN) is a structural and functional analogue of thalidomide that has demonstrated enhanced immunomodulatory properties and a more…”
Get full text

Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit by Thakkar, Snehal G., Fu, Alex Z., Sweetenham, John W., Mciver, Zachariah A., Mohan, Sanjay R., Ramsingh, Giridharan, Advani, Anjali S., Sobecks, Ronald, Rybicki, Lisa, Kalaycio, Matt, Sekeres, Mikkael A.

“…BACKGROUND. Predictors of outcome and rates of successful discharge have not been defined for patients with acute leukemia admitted to intensive care units…”
Get full text

Expression of bcl-2 in Classical Hodgkin's Lymphoma: An Independent Predictor of Poor Outcome by SUP, Stephen J, ALEMAHY, Carlos A, POHLMAN, Brad, ELSON, Paul, MALHI, Serena, THAKKAR, Snehal, STEINIE, Roxanne, HSI, Eric D

“…Although most classical Hodgkin's lymphoma (CHL) patients are cured, a significant minority fails primary therapy and may die as a result of their disease…”
Get full text

219 Prevalence of genomic alterations in XernaTM tumor microenvironment subtypes in colorectal cancer patients by Basu, Gargi D, LoBello, Janine, Thakkar, Snehal G, Aldrich, Jessica, Halbert, Matthew, Eimerman, Patrick, Flannery, Cynthia A, Therala, Nishitha, Hall, David W, Pointing, Daniel, Vohar, Lea, Lustrik, Roman, Ausec, Luka, Uhlik, Mark, Iyer, Seema, Benjamin, Laura, Baehner, Frederick L

“…BackgroundIn advanced colorectal cancer (CRC), analysis of the tumor microenvironment (TME) may be useful as a predictive biomarker, particularly supporting…”
Get full text

Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics by Thakkar, Snehal G, Choueiri, Toni K, Garcia, Jorge A

“…The endothelins (ETs), which include ET-1, ET-2, ET-3, and their receptors ET-A and ET-B, play a major role in tumor growth, proliferation, apoptosis,…”
Get full text

Intimal pulmonary artery sarcoma presenting as dyspnea: case report by Hsing, Jeff M, Thakkar, Snehal G, Borden, Ernest C, Budd, George T

“…We report a case of pulmonary sarcoma which is a rare cause of the common symptom of dyspnea. A fifty-one year old previously healthy male presented to the…”
Get full text

ESR1 alterations in gynecologic cancers by Balyimez, Aysegul, Basu, Gargi, White, Karen, Flannery, Cynthia A., Innis, Paige, Therala, Nishitha, Thakkar, Snehal, O’Shaughnessy, Joyce

Get full text

Oncogenic fusions in renal cell carcinoma by Basu, Gargi D., Kras, Katon, Flannery, Cynthia A., Tharayanil, Anson, Hall, David W., White, Karen, Thakkar, Snehal Govind, Gatalica, Zoran

“…475 Background: Detecting actionable or diagnostic fusions in solid tumors may significantly alter clinical decisions, including therapy selection. Some…”
Get full text

Genomic profiling of biliary tract carcinomas by their location by Gatalica, Zoran, Edwards, David K., Flannery, Cynthia A., Hall, David W., Hoag, Jess R, Therala, Nishitha, LoBello, Janine R., Thakkar, Snehal Govind, Basu, Gargi D., Abdelrahim, Maen

“…e16175 Background: Historically, biliary tract cancers have had a poor prognosis. Genomic profiling allows identification of alterations in genes with…”
Get full text

The genomic landscape of TERT alterations in bladder cancer by Jalkanen, Aimee, Basu, Gargi D., Hall, David W., Hoag, Jess R, LoBello, Janine R., Baehner, Frederick L., Thakkar, Snehal Govind, Dorff, Tanya B.

“…551 Background: Some of the most common mutations seen across cancers occur in TERT, where promoter mutations upregulate TERT transcription. In bladder cancer,…”
Get full text

Erythroblast transformation-specific transcription factor fusions in prostate cancer by Barbi de Moura, Michelle, Alyaqoub, Fadel S., Basu, Gargi D., Hall, David W., Hoag, Jess R, LoBello, Janine R., Baehner, Frederick L., Thakkar, Snehal Govind, Canfield, Steven

“…224 Background: Common drivers in advanced prostate cancer (PC) involve fusions of the 3’ DNA binding domain-containing region of an Erythroblast…”
Get full text

BRAF mutation classes and co-occurring mutations in NSCLC by Niu, Jiaxin, Flannery, Cynthia A., Hall, David W., Hoag, Jess W., Therala, Nishitha, Kemkes, Ariane C., Routh, Josh, De La O, Jean-Paul, Macera, Lisa, Thakkar, Snehal Govind

“…9083 Background: Targeted therapy against unique molecular drivers has revolutionized non-small cell lung cancer (NSCLC) treatment. BRAF mutations, present in…”
Get full text

Prevalence and genomic landscape of BRAF alterations across gastrointestinal cancers by Driscoll, David, Wang, Min, Alyaqoub, Fadel S., Udhane, Sameer S., Szelinger, Szabolcs, Jalkanen, Aimee, Hall, David W., Hoag, Jess R, LoBello, Janine R., Baehner, Frederick L., Thakkar, Snehal Govind, Basu, Gargi D.

“…806 Background: BRAF V600E mutations can lead to activation of the MEK/ERK pathway. The combination of dabrafenib plus trametinib was recently FDA-approved for…”
Get full text

Comprehensive whole-exome and transcriptome profiling to identify actionable alterations associated with response to PARP inhibitors in breast cancer by Dombrowski, Susan M., Udhane, Sameer S., Basu, Gargi D., Hall, David W., Hoag, Jess W., Alyaqoub, Fadel S., Noel, Pawan, Szelinger, Szabolcs, Wang, Min, Ozols, Audrey A., LoBello, Janine R., Thakkar, Snehal Govind, Baehner, Frederick L., O'Shaughnessy, Joyce

“…1096 Background: The use of targeted therapies identified using genetic and genomic approaches is now routine in breast cancer (BC). In this clinical lab…”
Get full text

Molecular profiling to identify potential therapeutic targets in hepatocellular carcinoma by Kundranda, Madappa N., Routh, Josh, Kemkes, Ariane C., Turner, Michelle, Therala, Nishitha, Hall, David W., Flannery, Cynthia A., Evans, Mark C., De La O, Jean-Paul, Thakkar, Snehal Govind

“…Abstract only 471 Background: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is often diagnosed at an advanced stage with…”
Get full text

Age-associated mutations in RAS -mutated versus RAS- nonmutated metastatic colorectal cancer by Kundranda, Madappa N., Kemkes, Ariane C., Routh, Josh, De La O, Jean-Paul, Evans, Mark C., Flannery, Cynthia A., Hall, David W., Therala, Nishitha, Turner, Michelle, Thakkar, Snehal Govind

“…Abstract only 171 Background: Mutational profiling is recommended for selecting targeted therapy for metastatic colorectal cancer (mCRC). Evidence suggests…”
Get full text

Abstract A070: Genomic profiling of pancreatic cancer by KRAS status by Basu, Gargi D., Thakkar, Snehal G., Hall, David W., Flannery, Cynthia A., Seerapu, Satish, Abdelrahim, Maen

“…Abstract Introduction: Ineffective treatments and late detection combine to give pancreatic cancer (PC) patients especially poor prognosis. However, as more…”
Get full text